Prescient Therapeutics bolsters board with appointment of experienced US-based pharma executive
Prescient Therapeutics Ltd (ASX:PTX) has strengthened its board through the appointment of experienced pharma executive Dr...
Prescient Therapeutics Ltd (ASX:PTX) has strengthened its board through the appointment of experienced pharma executive Dr...
Prescient Therapeutics (ASX: PTX), the Australian listed entity into clinical stage oncology, has released its...
Life science stocks have suffered heavily in 2022 due to investors shifting out of risk...
It’s the quarterly season again as the ASX market announcements page becomes increasingly flooded with...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has just presented at the Cell &...
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up...
Cell and gene therapy is changing the game when it comes to cancer treatment and...
Prescient Therapeutics is hoping to follow in the footsteps of Neuren Pharmaceuticals after positive results...
Telix Pharma (ASX:TLX) announced the US FDA has approved a supplementary New Drug Application (sNDA) for Illuccix,...
Prescient Therapeutics Limited (ASX:PTX) has shared an encouraging update for the ongoing clinical trial of...
This investor centre was built by Reach Markets
©2025 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.